Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Turn Therapeutics Inc.TTRX · Entity 5935 | See Remarks | April 01, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Turn Therapeutics Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.12 | Direct | 80,000 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 80,000 · Balance 80,000 F1: The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 12:06 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantEmployee stock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001213900-26-039712 · ownership.xml · derivative · entry 1 Chaudhary Zuraiz · CIK 0002086494 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · derivative.exercise_date: The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. F1 · derivative.expiration_date: The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 23:00 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | PurchaseCommon Stock | 2,500 | $3.50 | $8,750.00 |
DisclosureSEC source: 0001213900-25-121326 · ownership.xml · nonDerivative · entry 1 Chaudhary Zuraiz · CIK 0002086494 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 22:43 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | PurchaseCommon Stock | 1,000 | $3.29 | $3,290.00 |
DisclosureSEC source: 0001213900-25-113723 · ownership.xml · nonDerivative · entry 2 Chaudhary Zuraiz · CIK 0002086494 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 22:43 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | PurchaseCommon Stock | 1,450 | $2.61 | $3,784.50 |
DisclosureSEC source: 0001213900-25-113723 · ownership.xml · nonDerivative · entry 1 Chaudhary Zuraiz · CIK 0002086494 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 02:23 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | PurchaseCommon Stock | 2,500 | $3.62 | $9,050.00 |
DisclosureSEC source: 0001213900-25-111713 · ownership.xml · nonDerivative · entry 1 Chaudhary Zuraiz · CIK 0002086494 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,550 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.69, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 01:03 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | PurchaseCommon Stock | 5,050 | $4.95 | $24,997.50 |
DisclosureSEC source: 0001104659-25-101924 · tm2529397-2_4seq1.xml · nonDerivative · entry 1 Chaudhary Zuraiz · CIK 0002086494 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,050 Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 13:42 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantEmployee stock option (right to buy) · Derivative | 240,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-25-098569 · tm2528487-3_4seq1.xml · derivative · entry 1 Chaudhary Zuraiz · CIK 0002086494 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2035-10-07 F1 · derivative.exercise_date: Reflects an award of stock options to purchase shares of the Issuer's common stock granted under the Company's 2025 Omnibus Incentive Plan. 25% of the options shall vest on May 1, 2026, and 6.25% of the options shall vest in equal quarterly installments thereafter, in each case, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.